Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill, the Clinical Trial Modernization Act, promotes enrollment of underrepresented populations in clinical trials by funding community outreach, training, and partnerships; creates and clarifies safe harbors in anti-kickback law for sponsor payments covering trial-related expenses and digital health tools; permits sponsor payment of patient cost-sharing under strict conditions; excludes up to $2,000 of clinical trial payments from taxable income annually; and authorizes appropriations for FY2025–2026. It includes definitions tied to NIH and FDA guidance and non-federal-liability-limiting language for other protections.
Liberal emphasizes equity gains and removing participation barriers.
Relative to its intended legislative type, this bill is a focused substantive policy package that amends multiple statutes to lower financial and logistical barriers to clinical trial participation for underrepresented populations.
The bill, the Clinical Trial Modernization Act, promotes enrollment of underrepresented populations in clinical trials by funding community outreach, training, and partnerships; creates and clarifies safe harbors in anti-kickback law for sponsor payments covering trial-related expenses and digital health tools; permits sponsor payment of patient cost-sharing under strict conditions; excludes up to $2,000 of clinical trial payments from taxable income annually; and authorizes appropriations for FY2025–2026.
It includes definitions tied to NIH and FDA guidance and non-federal-liability-limiting language for other protections.
Broadly appealing goals but substantive statutory changes to fraud enforcement and tax treatment raise legislative and oversight resistance.
Relative to its intended legislative type, this bill is a focused substantive policy package that amends multiple statutes to lower financial and logistical barriers to clinical trial participation for underrepresented populations. It provides clear statutory language for safe harbors, conditions on sponsor payments, a limited tax exclusion, grant authorities, and effective dates.
Liberal emphasizes equity gains and removing participation barriers.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberal emphasizes equity gains and removing participation barriers.
Likely supportive overall because the bill reduces access barriers and targets underrepresented communities.
It advances equity by funding community outreach, multilingual materials, and by allowing expense coverage and digital tools to facilitate participation.
Cautiously positive: the bill addresses documented barriers to trial diversity while adding safeguards around payments.
Support hinges on clarity of anti-fraud protections, oversight, and budgetary discipline.
Skeptical overall because it creates exceptions to anti-kickback rules and a tax exclusion, raising potential fraud and fiscal concerns.
Some provisions expanding trial access could be acceptable if strictly limited.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Broadly appealing goals but substantive statutory changes to fraud enforcement and tax treatment raise legislative and oversight resistance.
The bill has not accumulated any surfaced votes yet.
Liberal emphasizes equity gains and removing participation barriers.
Broadly appealing goals but substantive statutory changes to fraud enforcement and tax treatment raise legislative and oversight resistance.
Relative to its intended legislative type, this bill is a focused substantive policy package that amends multiple statutes to lower financial and logistical barriers to clinical trial participation for underrepresented…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.